Nimbus Therapeutics Announces $105 Million Private Financing To Advance Pipeline Including Multiple Clinical Programs
Amount Raised
$105 Million
Round Type
Funding Round
BostonBiotechnologyHealth CareTherapeuticsPharmaceuticalDescription
Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the closing of a $105 million private financing round. The round was led by BVF Partners L.P. (BVF), with participation from existing investors including RA Capital Management and Atlas Venture. Access Biotechnology, Commodore Capital, Logos Capital, Surveyor Capital (a Citadel company), and a large alternative asset manager joined as new investors in this financing.
Who to call at Nimbus Therapeutics, and when
A new round usually means Nimbus Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nimbus Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nimbus Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nimbus Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nimbus Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Nimbus Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.